GSK's Shingles Vaccine Steps Closer To Catching Zostavax
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline is preparing for major filings next year for its challenger to Sanofi Pasteur MSD's Zostavax shingles vaccine, now named Shingrix (HZ/su vaccine), after promising top-line data in a second Phase III trial confirmed its benefits in an older patient population.